QCG
ALDX icon

Quadrant Capital Group’s Aldeyra Therapeutics ALDX Stock Holding History

Quadrant Capital Group’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$313 Hold
185
– – ﹤0.01% 2651
2025
Q4 		$959 Hold
185
– – ﹤0.01% 2601
2025
Q3 		$966 Buy
+185
New +$965 ﹤0.01% 2557

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrant Capital Group's ALDX Position: Q1 2026 in Review

Quadrant Capital Group held its Aldeyra Therapeutics (ALDX) position steady in Q1 2026 at 185 shares worth $313. The position accounts for ﹤0.01% of the portfolio, ranked #2651.

Quadrant Capital Group first reported a position in ALDX in Q3 2025 and has held it in 3 quarters since. The position peaked at $966 in Q3 2025. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Quadrant Capital Group held 185 shares of Aldeyra Therapeutics worth $313 as of Q1 2026.
  • Quadrant Capital Group left its Aldeyra Therapeutics share count unchanged in Q1 2026.
  • Aldeyra Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2651 holding.
  • Quadrant Capital Group first reported a position in Aldeyra Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Quadrant Capital Group's Aldeyra Therapeutics position peaked at $966 in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.